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Methamphetamine (METH) is abused worldwide, and it represents a threat for public health. METH exposure induces a variety of
detrimental eﬀects. In fact, METH produces a number of oxidative species, which lead to lipid peroxidation, protein misfolding, and
nuclear damage. Cell clearing pathways such as ubiquitin-proteasome (UP) and autophagy (ATG) are involved in METH-induced
oxidative damage. Although these pathways were traditionally considered to operate as separate metabolic systems, recent studies
demonstrate their interconnection at the functional and biochemical level. Very recently, the convergence between UP and ATG
was evidenced within a single organelle named autophagoproteasome (APP), which is suppressed by mTOR activation. In the
present research study, the occurrence of APP during METH toxicity was analyzed. In fact, coimmunoprecipitation indicates a
binding between LC3 and P20S particles, which also recruit p62 and alpha-synuclein. The amount of METH-induced toxicity
correlates with APP levels. Speciﬁc markers for ATG and UP, such as LC3 and P20S in the cytosol, and within METH-induced
vacuoles, were measured at diﬀerent doses and time intervals following METH administration either alone or combined with
mTOR modulators. Western blotting, coimmunoprecipitation, light microscopy, confocal microscopy, plain transmission electron
microscopy, and immunogold staining were used to document the eﬀects of mTOR modulation on METH toxicity and the
merging of UP with ATG markers within APPs. METH-induced cell death is prevented by mTOR inhibition, while it is worsened
by mTOR activation, which correlates with the amount of autophagoproteasomes. The present data, which apply to METH
toxicity, are also relevant to provide a novel insight into cell clearing pathways to counteract several kinds of oxidative damage.
1. Introduction
Methamphetamine (METH) is a highly addictive and neuro-
toxic drug, which causes a variety of neuropsychiatric alter-
ations mainly aﬀecting the dopamine (DA) mesostriatal
and mesolimbic systems in the brain [1, 2]. Exposure to
repeated doses of METH produces striatal DA depletion
and loss of mesostriatal DA terminals [3–12].
In the cell body of the substantia nigra pars compacta
(SNpc), METH produces alterations in the cytoplasm which
also occur in DA-PC12 cells and extend to the cytoplasm and
nucleus of striatal GABA neurons [6, 13–16]. These
alterations conﬁgure as multilamellar whorl staining for
ubiquitin, parkin, and alpha-synuclein [6, 15, 17]. Recent
studies indicate that high METH doses may reduce the num-
ber of nigral cell bodies [8, 18]. METH toxicity against DA
cell bodies and axons relates to an increase of DA release
and oxidative species [19]. In fact, METH alters the vesicular
storage of DA [20–22], it inhibits physiological DA metabo-
lism, which is naturally operated by MAO-A [23, 24], and
it reverts and/or inhibits the activity of the plasma membrane
DA transporter (DAT), thus leading to a loss of DAT-
binding sites [1, 25, 26]. All these eﬀects contribute to rise
of dramatically free DA levels within the cytosol of DA-
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containing cells. Since DA is no longer metabolized byMAO-
A, it undergoes self-oxidation and spontaneous conversion to
DA quinones, which in turn generate highly reactive oxida-
tive species [27, 28]. In this way, a redox imbalance is gener-
ated by METH, which is detrimental for the integrity of both
axon terminals and cell bodies where oxidized proteins,
lipids, and nucleic acids are generated [29, 30]. A key molec-
ular mechanism of protein oxidation consists in binding to
cysteinyl residues to generate disulphuric bridges, which alter
protein conformation [28, 31]. In this way, misfolded pro-
teins such as alpha-synuclein [6, 14], ubiquitin [6, 32], prion
protein [33], and parkin [6, 34] are generated. Again, METH
inhibits complex II of the mitochondrial respiratory chain,
which further elevates oxidative species and increases the
number of altered mitochondria [35–39]. METH also oxi-
dizes lipids to produce highly reactive by-products such as
4-hydroxynonenal [34, 40, 41]. All these oxidized substrates
represent a target for cell clearing systems, which promote
their removal. Thus, autophagy (ATG) and ubiquitin-
proteasome (UP) represent a powerful defense to counteract
redox imbalance generated by such a drug of abuse, and they
are both challenged by METH administration. In detail, UP
activity is inhibited by METH [13, 15, 16, 34], while UP
inhibitors produce subcellular alterations which overlap with
those produced by METH [6, 14, 42]. In line with this,
METH toxicity is enhanced by concomitant exposure to UP
inhibitors [15, 43]. ATG is quickly engaged during METH
in PC12 cells [22, 44] and in vivo, in the SNpc and striatum
[6, 15, 45]. Similarly to UP inhibitors, ATG blockers worsen
METH toxicity [37]. Despite a massive engagement of ATG,
which should sort neuroprotection, its activity is impaired by
METH itself since the high amount of substrates (misfolded
proteins and damaged mitochondria) engulfs this clearing
system [16, 37, 46]. Therefore, despite being ATG overex-
pressed following METH [22, 44], it is not considered to be
eﬀective due to a lack of its progression [37, 46]. Such a com-
bined defect in cell clearing systems produced by METH
paves the way to deleterious eﬀects induced by oxidative spe-
cies, which are abundantly produced by such a drug of abuse.
Recently, a cell clearing organelle, which possesses both
ATG and UP components, was described. This organelle
appears as a multilamellar vacuole, which carries both UP
and ATG key antigens [47]. This organelle corresponds to
the “autophagoproteasome” (APP) as being deﬁned in the
Glossary published in the consensus manuscript “Guidelines
for the Use and Interpretation of Assays for Monitoring
Autophagy (3rd Edition)” by Klionsky et al. [48]. In the
recent manuscript, it was demonstrated that APP is strongly
activated by mTOR inhibition [47]. In fact, when the mTOR
inhibitor rapamycin is administered, roughly all UP-positive
puncta detected by P20S immunostaining at confocal
microscopy move towards LC3-positive vacuoles, thus pro-
ducing a massive switch from cytosolic to compartmental-
ized proteasome [47]. Despite a strong involvement of UP
and ATG per se during METH toxicity, no study so far inves-
tigated what happens to this merging organelle. In the pres-
ent manuscript, we dissect the ultrastructural morphometry
of both UP and ATG components in diﬀerent cell compart-
ments, alone and in combination to merge within the autop-
hagoproteasome (APP), under the eﬀects of various METH
doses at diﬀerent time intervals. A variety of techniques were
used to investigate these eﬀects encompassing plain light
microscopy, confocal microscopy, transmission electron
microscopy, Western blotting, and coimmunoprecipitation.
In detail, we aimed to assess whether (i) the autophagopro-
teasome was operating in the DA-containing PC12 cell line,
(ii) the autophagoproteasome was modiﬁed followingMETH
exposure, (iii) the amount of this organelle was associated
with the modulation of METH toxicity, and (iv) whether
these phenomena depend on mTOR activity as tested during
either mTOR inhibition or activation.
2. Materials and Methods
2.1. Cell Cultures. In the current study, we chose the rat pheo-
chromocytoma PC12 cell line, since these cells are able to
synthetize and release DA and they express DA receptors
on their external membrane. This is key in the case of METH,
which exerts its mechanisms of action mainly by aﬀecting
molecular targets, which regulate DA transmission. In fact,
the presence of DA and DA receptors, as well as DA uptake
mechanisms, renders PC12 cell lines closer to DA terminals
compared with their ancestors (i.e., chromaﬃn cells of
the adrenal medulla). This concept is reinforced by the
presence of the isoform of monoamine oxidase (MAO)
type A, which characterizes also DA neurons, contrasting
with the established prevalence of MAO type B within chro-
maﬃn cells of the adrenal medulla. Therefore, PC12 cells
represent a model to predict the neurotoxicity of METH
on central DA neurons with signiﬁcant implications for
the treatment of neuropsychiatric and neurodegenerative
disorders [49].
The PC12 cell line was obtained from a cell bank (IRCCS
San Martino Institute, Genova). The cells were grown in
RPMI 1640 medium (Sigma-Aldrich, St. Louis, MO, USA)
supplemented with heat inactivated 10% horse serum (HS,
Sigma) and 5% fetal bovine serum (FBS, Sigma), penicillin
(50 IU/ml)/streptomycin (50mg/ml, Sigma), under standard
culture conditions in a humidiﬁed atmosphere containing
5% CO2 at 37
°C. Experiments took place during the log phase
of cell growth. At this time, cells were seeded into cell culture
plates and they were incubated at 37°C in 5% CO2 for further
24 hours. In particular, for transmission electron microscopy
(TEM) and coimmunoprecipitation experiments, 1× 106
PC12 cells were seeded in culture dishes in a ﬁnal volume
of 5ml. For Western blotting, 5× 105 cells were seeded in
six-well plates in a ﬁnal volume of 2ml/well. Finally, for con-
focal microscopy experiments, 5× 104 cells were grown on
polylysine slides placed in 24-well plates at a ﬁnal volume
of 1ml/well.
In order to study METH-induced toxicity, PC12 cells
were treated with diﬀerent doses of METH (1nM, 10 nM,
100 nM, 1μM, and 10μM) for 72 hours. In a second set of
experiments, PC12 cells were treated with 1μM or 10μM
of METH for diﬀerent time exposures (12, 24, and 72hours).
A study fromMelega et al. [50] reports data deriving from an
i.v. intake of 1000mg/day METH in humans, approximately
corresponding to 10mg/kg, which can produce neurotoxicity
(i.e., loss of DA terminals and neurons) in mice. However,
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since the present study was designed to assess the ultrastruc-
tural eﬀects of METH on speciﬁc subcellular organelles, apart
from neurotoxicity, we chose METH doses from 1μM to
10μMbased on the previous studies [6, 15, 37]. In our hands,
at doses between 10 and 100μM of METH in PC12 cell lines,
only a few cells survive, and this is further exacerbated by
METH doses above 100μM [6, 43]. This is also due to intrin-
sic vulnerability of PC12 cells to DA-increasing agents, which
explains such a discrepancy with DA neurons [49]. In fact,
PC12 cells possess inherent features, which render these cells
particularly sensitive to high doses of DA. These include (i)
the presence of VMAT-1, which is less speciﬁc for the vesic-
ular uptake of catecholamines when compared with its
homolog VMAT-2 expressed in the brain, and (ii) low levels
of the DAT, thus reduced cytosolic reuptake of DA. Thus,
these cells have a limited ability to adapt the neurotransmit-
ter synthesis and vesicle traﬃcking/release to the synaptic
needs, which contrasts with the ﬂexibility of DA neurons to
respond appropriately to a releasing stimulus.
Further experiments were carried out to evaluate the
eﬀects produced on METH toxicity and APP components
by the modulation of mTOR activity. In these experi-
ments, cells were exposed to 100 nM rapamycin and
50mM asparagine, alone or in combination with 10μM
METH, for 72 hours. When it was combined with METH,
rapamycin was added 2h before METH, while asparagine
was administered 30min before METH. The doses of
asparagine and rapamycin were selected based on the pre-
vious papers [32, 47]. However, to validate these doses in
these experimental conditions, the inhibition or activation
of mTOR activity for each compound was tested by mea-
suring the downstream product pS6.
METH and asparagine were dissolved directly in the cul-
ture medium. Dilutions of rapamycin were obtained by a
stock solution (1mM of rapamycin dissolved in the culture
medium containing 10% DMSO).
2.2. Transmission Electron Microscopy. PC12 cells were cen-
trifuged at 1000g for 5min. After removal of the supernatant,
the pellet was rinsed in PBS before being ﬁxed. The ﬁxing
procedure was carried out with a solution containing 2.0%
paraformaldehyde and 0.1% glutaraldehyde in 0.1M PBS
(pH7.4) for 90min at 4°C. This aldehyde concentration min-
imally covers antigen epitopes, while fairly preserving tissue
architecture. After removal of the ﬁxing solution, specimens
were postﬁxed in 1% OsO4 for 1 h at 4
°C; they were dehy-
drated in ethanol and ﬁnally embedded in epoxy resin.
For ultrastructural morphometry, grids containing non-
serial ultrathin sections (40–50nm thick) were examined at
TEM, at a magniﬁcation of 8000x. Several grids were ana-
lyzed in order to count a total number of 50–100 cells for
each experimental group. In particular, when counting cell
death, 50 cells per group were sampled, while 50 cells per
group were sampled to carry out ultrastructural morphome-
try and immunogold counts; when counting APP, 100 cells
per group were used. Each count was repeated at least 3 times
by three blind observers.
Plain TEMwas implemented by a postembedding immu-
nocytochemistry procedure for antibodies against LC3 and
P20S, which were used as markers of ATG and UP pathways,
respectively. Antibody speciﬁcity was assessed by a number
of studies which were partially reported in Table 1 (extramu-
ral evidence), and they were routinely used for at least 10
years in our lab (intramural evidence) [51–76].
It is worth mentioning that LC3 and P20S antigens were
chosen as markers of ATG vacuoles (LC3 alone) or APP vac-
uoles (LC3 combined with P20S) accordingly to the manu-
script “Guidelines for the Use and Interpretation of Assays
for Monitoring Autophagy (3rd Edition)” [48].
Sometimes, in order to validate the count for ATG vacu-
oles, beclin 1 was used instead of or in combination with LC3
for detecting early time points. No signiﬁcant diﬀerence
between LC3- and beclin 1-based counts was detected; thus,
results fully express the amount of LC3. At the end of the
plain TEM or immunocytochemistry procedure, ultrathin
sections were stained with uranyl acetate and lead citrate,
and they were ﬁnally examined using a JEOL JEM-100SX
transmission electron microscope (JEOL, Tokyo, Japan).
2.2.1. Postembedding Immunocytochemistry. Fixing and post-
ﬁxing solutions and the use of epoxy resin were validated in
our previous studies for immunogold-based ultrastructural
morphometry [47]. In fact, a combination of aldehydes,
OsO4, and epoxy resin allows a minimal epitope covering,
while preserving cell ultrastructure [47, 77, 78]. In particular,
OsO4 binds to cell membranes, thus enhancing the contrast
of cytosolic compartments, and it prevents the formation of
membrane’s artifacts, which may mimic vacuoles. Moreover,
epoxy resin is advantageous over acrylic resin in preserving
cell morphology.
Postembedding procedure was carried out on ultrathin
sections collected on nickel grids, which were incubated on
droplets of aqueous sodium metaperiodate (NaIO4), for
30min, at room temperature in order to remove OsO4.
NaIO4 is an oxidizing agent allowing a closer contact
between antibodies and antigens by removing OsO4 [77].
This step improves the visualization of immunogold particles
speciﬁcally located within a sharp context of cell integrity,
and it allows the counting of molecules within speciﬁc cell
compartments. Then, grids were washed in PBS and incu-
bated in a blocking solution containing 10% goat serum
and 0.2% saponin for 20min, at room temperature. Grids
were then incubated with the primary antibody solution con-
taining both rabbit anti-LC3 (Abcam, Cambridge, UK,
diluted 1 : 50) and mouse anti-P20S (Abcam, Cambridge,
Table 1: Sources and references for antibodies reported in the
present study.
Antibodies References
LC3 (Abcam) [47, 51–54]
LC3 (Sigma) [55–57]
Proteasome 20S (Abcam) [47, 58–61]
Alpha-synuclein (BD Biosciences) [62–66]
SQSTM1-p62 (Abcam) [67–71]
Phospho-p70 S6 kinase (Thr421/Ser424) (Cell
Signaling Technologies)
[72–76]
3Oxidative Medicine and Cellular Longevity
UK, diluted 1 : 50), with 0.2% saponin and 1% goat serum in a
humidiﬁed chamber overnight, at 4°C. After washing in PBS,
grids were incubated with the secondary antibodies conju-
gated with gold particles (10 nmmean diameter, for gold par-
ticle anti-rabbit; 20 nm mean diameter, for gold particle anti-
mouse, BB International), diluted 1 : 30 in PBS containing
0.2% saponin and 1% goat serum for 1 h, at room tempera-
ture. Control sections were incubated with the secondary
antibody only. After washing in PBS, grids were incubated
on droplets of 1% glutaraldehyde for 3min; additional exten-
sive washing of grids on droplets of distilled water was
carried out to remove extensive salt traces and prevent
precipitation of uranyl acetate.
2.2.2. Ultrastructural Morphometry. In order to distinguish
vacuoles (ATG from APP) and to count immunogold par-
ticles (ranging from 10nm to 20nm), observations were
performed directly at TEM at a magniﬁcation of 8000x
[79] since this represents the minimal magniﬁcation at
which immunogold particles and all cell organelles can
be concomitantly identiﬁed.
We started to count from a grid square corner in order to
scan the whole cell pellet within that grid square, which was
randomly identiﬁed. Assessments of vacuoles and measure-
ment of immunogold particles were carried out according
to Lenzi et al. [47].
Brieﬂy, we counted the number of unstained vacuoles per
cell as vacuoles with single, double, or multiple membranes
possessing the same electron density of the surrounding cyto-
plasm or partly containing some electron dense structure. In
each cell, we counted the total number of immunogold anti-
LC3 and/or anti-P20S particles placed either in the cytoplasm
or within vacuoles and we expressed the number of immuno-
gold particles as the mean per cell. Finally, we counted the
number of APPs per cell as a single, double, and multiple
membrane vacuoles, in which immunogold particles of LC3
(10nm) and P20S (20nm) were colocalized.
2.3. Light Microscopy. For light microscopy, PC12 cells were
harvested and centrifuged at 800g for 5min to obtain a pellet,
which was further resuspended in 0.5ml of the culture
medium in order to obtain a dense cell suspension. This
was layered on glass slide spinning at 15,000g for 10min by
cytospin (Cytospin 4, Thermo Fisher).
2.3.1. Haematoxylin and Eosin Staining and Cell Count. Cells
were ﬁxed with 4% paraformaldehyde in PBS for 15min and
plunged in PBS and then in haematoxylin solution (Sigma)
for 20min. Haematoxylin staining was stopped by washing
in distilled water and followed by plunging cells in the eosin
solution (Sigma) for a few min. After repeated washing to
remove the excess of dye, cells were dehydrated in increasing
alcohol solutions, clariﬁed in xylene, and ﬁnally covered with
the DPX mounting medium (Sigma). Cell count was per-
formed at light microscopy at 40x magniﬁcation. Brieﬂy,
for each experimental group, the number of stained cells
detectable after each speciﬁc treatment was counted and
expressed as a percentage of the control group. These values
represent the means of six independent cell counts.
Moreover, we counted the number of giant cells occa-
sionally observed after 10μMMETH.We considered as giant
cells those owning a diameter higher than 14–15μm. The
amount of giant cells out of the total number of cells counted
on the glass slide was expressed as a percentage, for each
experimental group. The values represent the means of six
independent cell counts.
2.3.2. Trypan Blue. For trypan blue staining, PC12 cells were
seeded at a density of 1× 104 cells/well and they were prein-
cubated for 24 h. After METH treatments, PC12 cells were
collected and centrifuged at 800g for 5min. The cell pellet
was suspended in the culture medium, and 25μl of cell sus-
pension was added to a solution of 1% trypan blue (62.5μl)
and PBS (37.5μl). Cells were then incubated for 10min, at
room temperature. Soon after, 10μl aliquot of this solution
was counted at light microscopy using a Bürker glass cham-
ber. Viable and nonviable cells were counted, and cell death
was expressed as percentage of trypan blue frankly positive
cells out of the total cells. The values represent the means of
three independent cell counts.
2.4. Confocal Microscopy. PC12 cells were washed in PBS and
ﬁxed with paraformaldehyde 4% for 5min at room tempera-
ture. Antigen retrieval was carried out in 100mM Tris-HCl,
5% urea at 95°C, for 10min. After washing in PBS, cells were
permeabilized in 0.2% Triton X-100, for 10min. They were
blocked in PBS containing 0.1% Tween-20, supplemented
with 1% bovine serum albumin (BSA) and 23mg/ml of gly-
cine, for 30min. Afterwards, cells were incubated overnight
at 4°C in 1% BSA in PBS-T containing 1 : 50 anti-LC3 anti-
body (Abcam) and 1 : 30 anti-P20S (Abcam). Finally, cells
were incubated for 1 h with ﬂuorophore-conjugated second-
ary antibodies (1 : 200; goat anti-rabbit Alexa 488 and goat
anti-mouse Alexa 594, Molecular Probes, Life Technologies)
in 1% BSA in PBS-T at room temperature. Then, cells were
washed in PBS, and they were mounted in ProLong Diamond
Antifade Mountant (Molecular Probes, Life Technologies).
The analysis was performed using a Leica TCSSP5 confocal
laser scanning microscope (Leica Microsystems, Mannheim,
Germany) using a sequential scanning procedure. Confocal
images were collected every 400 nm intervals through the z
-axis of each section by means of 63x oil lenses. Z-stacks of
serial optical planes were analyzed using the Multicolor
Package software (Leica Microsystems). Negative controls
were carried out by omitting primary antibodies.
2.5. Coimmunoprecipitation Assay. PC12 cells were homoge-
nized at 4°C in an ice-cold lysis buﬀer. One microliter of
homogenates was used for protein determinations. 30μg
of proteins from whole cell lysates was loaded to perform
Western blotting before coimmunoprecipitation. β-Actin
was used as a loading control for protein levels from the
whole cell lysates, on which immunoprecipitation of LC3
was then performed.
Proteins (800μg) were incubated at 4°C overnight with
primary rabbit anti-LC3 antibody (2μg for each sample;
Sigma-Aldrich, Milan, Italy). The antibody/antigen complex
was pulled out of the sample using protein A-Sepharose
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beads. This process isolated the protein of interest from the
rest of the sample. Proteins were separated on sodium dode-
cyl sulphate-polyacrylamide gel (12%) and transferred on
immuno-PVDF membrane (Bio-Rad, Milan, Italy) for 1 h.
Filter was blocked for 1 h in Tween-20 Tris-buﬀered saline
(TTBS) (100mM Tris-HCl, 0.9% NaCl, 1% Tween 20,
pH7.4) containing 5% nonfat dry milk. Blot was incubated
at 4°C overnight with mouse monoclonal primary antibody
anti-P20S (1 : 100, Abcam), mouse monoclonal anti-alpha-
synuclein (1 : 1000, BD Biosciences), and rabbit monoclonal
anti-SQSTM1 (anti-p62, 1 : 1000, Abcam, Milan, Italy); it
was washed 3 times with the TTBS buﬀer and then incubated
for 1 h with secondary peroxidase-coupled antibody (anti-
mouse, 1 : 7000; anti-rabbit, 1 : 7000; Calbiochem, Milan,
Italy). Then, blot was stripped with a solution of distilled
water and 3.5% acetic acid in the presence of 1% NaCl 5M.
Blot was kept in this solution for 20min, and then, it was
washed in TTBS (8 washes for 5min). Finally, to verify the
correct immunoprecipitation, blot was incubated with pri-
mary rabbit anti-LC3 antibody (1 : 6000, Sigma-Aldrich),
for 1 h, at room temperature. Filter was washed 3 times with
the TTBS buﬀer and then incubated for 1 h with secondary
peroxidase-coupled antibody (anti-rabbit, 1 : 7000; Calbio-
chem, Milan, Italy). Immunostaining was revealed by
enhanced chemiluminescence (GE Healthcare, Milan, Italy).
The total amount of proteins measured through optical
density was normalized for total β-actin, which was mea-
sured in whole cell lysates, since β-actin is not present
in LC3 immunoprecipitates. Thus, readers should consider
that such a normalization could not refer to the immuno-
precipitated blotted proteins, but rather to the total
amount of proteins in the very same cells used to carry
out the immunoprecipitate.
2.6. Western Blotting. PC12 cells were lysed in a buﬀer
(100mM Tris-HCl, pH7.5, 5M NaCl, 0.5m EDTA, 10%
SDS, 1% NP40, IGEPAL), containing protease and phospha-
tase inhibitor, and centrifuged at 15,000g for 20min at
4°C. The supernatant was collected, and protein concentra-
tion was determined using a protein assay kit (Sigma).
Samples containing 40μg of total proteins were solubilized
and electrophoresed on a 12% sodium dodecyl sulphate-
(SDS-) polyacrylamide gel. Following electrophoresis,
proteins were transferred to the nitrocellulose membrane
(Bio-Rad Laboratories, MI, Italy). The membrane was
immersed in a blocking solution (3% nonfat dried milk in
20mM Tris and 137mM NaCl at pH7.6 containing 0.05%
Tween-20) for 2 h on a plate shaker. Subsequently, the mem-
brane was incubated with mouse anti-pS6 primary antibody
(1 : 2000; Millipore, Burlington, MA, USA) overnight at 4°C
on the plate shaker. Blot was probed with horseradish
peroxidase-labeled secondary antibodies, and the bands were
visualized with enhanced chemiluminescence reagents
(Bio-Rad Laboratories). Image analysis was carried out by
ChemiDoc System (Bio-Rad Laboratories).
2.7. Statistics. For ultrastructural morphometry data were
given as an absolute number concerning the following mea-
surements: (i) unstained vacuoles, (ii) LC3-positive vacuoles,
(iii) P20S-positive vacuoles, (iv) LC3+P20S-positive vacu-
oles (APP), and (v) immunogold particles (including LC3
and P20S). Ratios were used to express (i) the number
of LC3 immunogold particles within vacuoles out of the
number of cytoplasmic LC3 immunogold particles and
(ii) the number of P20S immunogold particles within vac-
uoles out of the number of cytoplasmic P20S immunogold
particles. All data were reported as the means± SEM per
cell from 50 cells per group in all counts but the LC3
+P20S which was expressed as the means± SEM from
100 cells per group.
Data on the amount of cell death were expressed as the
percentage of the mean± SEM dead cells out of the total cell
number in each grid being analyzed (i.e., 5 total grids, each
containing at least 10 cells, for a total of 50 cells for each
experimental group).
For confocal microscopy, the amount of P20S+LC3
puncta was counted. Values were expressed as the mean
number of puncta± SEM per cell counted in each slide in
two separate experiments (each one carried out in duplicate).
For Western blot optical density was expressed as the
means± SEM calculated in six separate experiments.
All statistical analyses were carried out by using one-way
analysis of variance, ANOVA, followed by Sheﬀè’s post hoc
analysis. Null hypothesis (H0) was rejected for p ≤ 0 05.
3. Results and Discussion
3.1. Dose and Time Dependencies of METH-Induced
Unstained Vacuoles. Conﬁrming previous data, METH admin-
istration for 72h ﬁlled catecholamine cells with vacuoles, as
reported in representative micrographs (Figure 1(a)) and
counted in the graph of Figure 1(b). As measured in
Figure 1(b), unstained vacuoles increase dose-dependently
within a wide range of METH doses (from 1nM up to
1μM). At the dose of 1μM, the number of METH-induced
unstained vacuoles reached the peak. Whereas, for the highest
dose of METH (10μM), the number of unstained vacuoles
dropped down to levels measured following low METH doses
(1nM and 10nM). This suggests that at 10μM METH dose,
toxicity occludes the development of novel intracellular struc-
tures, even in spared cells. Therefore, the doses of METH
1μM and 10μM were chosen for the time dependence study.
As reported in representative micrographs of Figure 1(c), a
time-dependent increase of unstained vacuoles was produced
by METH at the 1μM dose from 12h up to 72h. These
eﬀects were evidenced by staining with arrows the unstained
vacuoles in each experimental condition to relate representa-
tive pictures to counts reported in the graph in Figure 1(d).
As expected, even the dose of 10μM METH at 72h time-
dependently increases the number of unstained vacuoles
(Figure 1(f)). This was evident in representative micrographs
of Figure 1(e); we investigated the eﬀects of such a METH
dose at earlier time intervals (representative pictures of
Figure 1(e)). These eﬀects were evidenced by staining with
arrows the unstained vacuoles at each time interval to relate
representative pictures to counts reported in the graph in
Figure 1(f). The number of unstained vacuoles is consistent
with the time course and dose dependency of multilamellar
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Figure 1: Continued.
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bodies produced by METH, which we previously described
under a diﬀerent name (whorls) in this cell line [6].
3.2. Dose and Time Dependencies of METH-Induced Cell
Death.When assessing the eﬀects produced by a 10μM dose
of METH, there was a dramatic increase (roughly by half)
in the amount of cell loss compared with controls and
occasionally, giant cells appeared, which were never
observed in controls (representative H&E staining of
Figures 2(a) and 2(b); graph of Figure 2(c)). The counts
for surviving cells carried out at H&E staining revealed a
dose- and time-dependent decrease in cell survival (graphs
of Figures 2(d) and 2(e), respectively). This was dramatic
at 72 h following 10μM METH. These same results were
reproduced by trypan blue-positive counts for dying cells,
which conﬁrmed a dose- and time-dependent increase in
dying cells (graphs of Figures 2(f) and 2(g), respectively).
A similar phenomenon (cell death in the same range of
doses and times induced by METH administration) was
detected at TEM (representative TEM micrographs of
Figures 2(g) and 2(h), respectively). The count of dying
cells (either necrotic or apoptotic) at TEM for METH and
controls (Figures 2(h) and 2(i), respectively) was overlap-
ping with that reported for trypan blue staining. Remark-
ably dying cells were higher than controls also following
the dose of 1μM (at 72 h, Figures 2(j) and 2(k)). The
pronounced toxicity induced by 10μM METH is likely to
impair cell metabolism even in spared cells, which when
analyzed at 72 h own much less vacuoles compared with
other doses.
3.3. METH Alters Dose and Time Dependency of the Amount
and Placement of LC3 Particles. In order to identify ATG and
UP components within METH-treated cells, we carried out
ultrastructural morphometry by using 10nm immunogold
particles to reveal LC3, while 20nm immunogold particles
were used to stain P20S. Following METH administration,
an increase in LC3-stained vacuoles was detected starting at
the dose of 100nMMETH, while no increase compared with
controls was counted in a lower range of doses (between
1nM and 10nM, Figure 3(a)). This was quite unexpected
since the count of unstained vacuoles provided in
Figure 1(b) indicates a signiﬁcant increase (almost two-fold)
compared with controls even at the dose of 1 nM METH.
This is a key point, since unstained vacuoles are considered
to correspond to pure ATG vacuoles. Thus, one would expect
an overlapping between unstained and LC3-positive vacu-
oles. Such a discrepancy leaves the issue open on which the
nature of METH-induced unstained vacuoles might be. In
fact, these vacuoles were induced by METH administration
since they increased two-fold compared with controls at the
dose of 1 nM and 10nM METH.
A lack of LC3 staining in these vacuoles for low METH
doses suggests that these may not correspond to authentic
ATG vacuoles, although they increase two-fold with respect
to controls. Although the nature of these unstained vacuoles
remains to be deﬁned, the possibility exists that LC3 particles
moving within ATG vacuoles remain undetected for these
low METH doses. However, as shown in the graph of
Figure 3(b), total LC3 particles in the cell for 1 nM and
10nM METH do not increase either. This indicates a lack
of ATG induction for low METH doses. Another possibility
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Figure 1: METH increases the amount of unstained vacuoles dose- and time-dependently. (a) Dose-dependent representative pictures of
unstained vacuoles (arrows) of control and METH at 72 h treated cells at diﬀerent doses. (b) Dose-dependent graph of unstained vacuoles
per cell at 72 h. (c) Time-dependent representative pictures of unstained vacuoles (arrows) of control and 1μM METH-treated cells. (d)
Time-dependent graph of unstained vacuoles per cell of control and 1μM METH-treated cells. (e) Time-dependent representative pictures of
unstained vacuoles (arrows) of control and 10μM METH-treated cells. (f) Time-dependent graph of unstained vacuoles per cell of control
and 10μM METH-treated cells. Values are given as the mean number of unstained vacuoles, which were counted in 50 cells per group. Error
bars represent the standard error of the mean. ∗p ≤ 0 05 vs. control; ∗∗p ≤ 0 05 vs. other groups. N=nucleus. Scale bar = 1μm.
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Figure 2: METH induces cell death time- and dose-dependently with a maximal eﬀect at the 1 μM and 10 μMdoses. (a) Representative H&E-
stained picture from controls. (b) Representative H&E-stained picture following 10μMMETH at 72 h. (c) Graph reporting the percentage of
giant cells counted in H&E-stained total cells from controls and METH at 72 h. (d) Dose-dependent graph of H&E-stained cells from control
and METH at 72 h. (e) Time-dependent graph of H&E-stained cells from control and 10μMMETH-treated cells. (f) Dose-dependent graph
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deals with the dynamics of ATG vacuoles, which could mat-
urate before LC3 is increased. This hypothesis remains
unlikely, since other markers, such as beclin 1, which stains
ATG vacuoles earlier than LC3, do not provide any staining
either. Moreover, LC3 staining is a gold standard to deﬁne
autophagosomes, and 72 h should be enough to complete
the process. Instead, even at this time interval for low
(1 nM and 10nM) METH doses, LC3 particles do not
increase in any cell compartments including the cytosol. This
suggests that 1 nM and 10nM METH do not really increase
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Figure 3: METH alters the amount and placement of LC3 and P20S particles dose-dependently, with P20S being more sensitive than LC3. (a)
Dose-dependent graph of the number of LC3-positive vacuoles per cell from controls and METH at 72 h. (b) Dose-dependent graph of total
LC3 particles per cell from controls andMETH at 72 h. (c) Representative micrograph of LC3-positive vacuole from 10μMMETH at 72 h. (d)
Dose-dependent graph of the ratio between the numbers of LC3 particles within vacuoles with respect to cytosolic LC3 particles from controls
and METH at 72 h. (e) Dose-dependent graph of the number of P20S-positive vacuoles per cell from controls and METH at 72 h. (f) Dose-
dependent graph of total P20S particles per cell from controls and METH at 72 h. (g) Representative micrograph of P20S-positive vacuoles
from 10μM METH at 72 h. (h) Dose-dependent graph of the ratio between the numbers of P20S particles within vacuoles with respect to
cytosolic P20S particles from controls and METH at 72 h. Values are given as the mean number of LC3 or P20S particles and vacuoles
counted in 50 cells per group. Error bars represent the standard error of the mean. ∗p ≤ 0 05 vs. control; ∗∗p ≤ 0 05 vs. other groups; #p ≤
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(10 nm) or P20S (20 nm) within vacuoles; asterisk (∗) indicates P20S in the cytosol (c) and LC3 in the cytosol (g). Scale bar = 200 nm.
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ATG. Therefore, unstained vacuoles, which minimally
occur in control cells and selectively increase following
very low METH doses, are likely to belong to other path-
ways (such as the exosomal compartment). This hypothe-
sis is currently under investigation in the lab. Vacuolar
compartments other than ATG may be recruited for low
METH doses. It is likely that DA turnover promoted by
METH increases vesicle recycling, which may account for
these unstained vacuoles. On the other hand, the lowest
eﬀects of METH on membrane traﬃcking may aﬀect other
compartments such as retromers or exosomes, which are
more bound to cell release than ATG activation.
The increase in vacuoles measured for doses above
10 nM corresponds to LC3-positive (ATG) vacuoles. Data
on the amount of LC3-positive vacuoles (shown in represen-
tative Figure 3(c)) parallels data on LC3 particles reported in
the graph of Figure 3(b). In fact, they increase signiﬁcantly
only at the dose of 100nM, while they do not diﬀer from
controls at low METH doses (1 nM and 10nM METH).
Thus, METH increases LC3 particles (Figure 3(b)) and
LC3-positive vacuoles (Figure 3(a)) only at doses higher
than 10nM, although no compartmentalization of LC3
within vacuoles is produced by any dose of METH (graph
of Figure 3(d)). In contrast, the trend indicates a dispersion
rather than a polarization of LC3 particles from cell vacuoles
towards the cytosol. This is indicated by the ﬁnding that the
ratio of vacuolar vs. cytosolic LC3 particles following METH
decreases dose-dependently (Figure 3(d)), which indicates a
METH-induced loss of LC3 compartmentalization. Such an
uncoupling between LC3 and ATG vacuoles is a novel ﬁnd-
ing in METH toxicity. In fact, so far, METH was thought to
impair ATG machinery by engulﬁng ATG vacuoles, which
become stagnant and ﬁlled with LC3. The present data show
that, under METH, ATG vacuoles are impaired already in
their maturation. In fact, for low METH doses, LC3 is not
increased, while for higher METH doses, LC3 increases
more in the cytosol than within vacuoles. It looks like that
in these conditions (METH doses up to 1μM), the drive
which polarizes LC3 towards the ATG machinery is weak-
ened. At 10μM METH, there is a further drop in the ratio
between vacuolar and cytosolic LC3 particles, which is likely
to be due to a concomitant loss of cell ability to build organ-
elles for toxic METH doses. This latter ﬁnding is conﬁrmed
by the fact that 10μM METH strongly increases free LC3
particles compared with the dose of 1μM, but the number
of LC3-positive ATG vacuoles at 10μM is roughly a half of
that counted at 1μM.
These observations, despite being unexpected, provide
also novel methodological insights into ATG. In fact, when
using confocal microscopy following high METH doses,
there is a strong increase in LC3 immunoﬂuorescence, which
is routinely interpreted as produced by stagnant vacuoles.
However, ultrastructural morphometry demonstrates that
an increase in LC3 immunostaining is indeed driven by
free cytosolic noncompartmentalized LC3 rather than by
vacuolar LC3.
We may summarize these latter data by stating that,
under METH administration, there is a loss of compartmen-
talization of LC3 particles within vacuoles, despite an
increased amount of both LC3 particles and vacuoles per se,
which represents a novel insight in ATG and METH toxicity.
This leads to reconsider the signiﬁcance of densely ﬂuo-
rescent LC3 spots detected at confocal microscopy following
METH [16, 80]. The stoichiometric counts at TEM demon-
strate that a greater contribution is provided by free cytosolic
LC3. This is representatively evidenced in micrograph of
Figure 3(c), and it is remarked by the ratio between compart-
mentalized LC3 particles in ATG vacuoles and free cytosolic
LC3 particles (graph of Figure 3(d)). This demonstrates a
lack of METH-induced LC3 compartmentalization with a
trend towards “METH-induced LC3 dispersion.” This is
frankly evident for a neurotoxic dose of METH (10μM)
where a loss of ﬁne subcellular compartments take place. As
discussed for Figure 1(b), this is likely to reﬂect a degenera-
tion of the subcellular trim of spared cells, which organize
protein traﬃcking, where the ability to create various cell
compartments is reduced.
3.4. METH Alters the Amount and Placement of P20S
Particles. When counting P20S-positive vacuoles, these were
consistently decreased compared with controls for all METH
doses (Figures 3(e) and 3(g)). These ﬁndings were repro-
duced when counting P20S immunogold particles, which
were markedly decreased following all METH doses (ranging
between 1nM and 10μM, Figure 3(f)). Remarkably, this was
replicated even for the highest dose of 10μM METH, which
was shown to suppress compartmentalization of LC3 within
vacuoles (Figure 3(d)). It is likely that such a discrepancy is
related to a diﬀerent sensitivity of P20S compared with LC3
to the eﬀects of METH. Again, no polarization of P20S
towards vacuoles was induced by METH, which left the ratio
unmodiﬁed between P20S particles within vacuoles and cyto-
solic P20S particles compared with controls (Figure 3(h)),
although the trend was diﬀerent compared with LC3.
It is surprising that the eﬀects induced by METH on
the number of the ATG marker LC3 follow a diﬀerent
dose-response curve compared with the eﬀects induced
on the number of the UP marker P20S. In fact, in the
range of 1 nM to 10nM doses, no alterations were pro-
duced by METH in the number of LC3 immunogold par-
ticles (Figure 3(b)), while at the dose of 1 nM of METH,
the reduction of P20S immunogold particles was already
maximal (roughly, a half of controls, Figure 3(f)). This
suggests that the biochemical pathways involved (regulat-
ing either ATG or UP) possess a diﬀerent dose-response
curve being the UP maximally aﬀected already at the low-
est dose of METH. Thus, the P20S protein component is
markedly sensitive to doses of METH, which are likely
to be in the picomolar range.
As previously discussed, the lowest dose of METH (1nM)
doubled the number of unstained vacuoles without aﬀecting
neither LC3 particles nor LC3 vacuoles. In contrast, this very
same dose reduced roughly to a half both P20S particles and
P20S-positive vacuoles. It is worth noting that this METH
dose is suﬃcient to double the DA release in PC12 cells [6].
Thus, it is likely that an increased amount of free DA may
already impair the P20S proteasome. This is consistent with
our previous study showing that, at the dose of 1 nM of
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METH, P20S is already suppressed [43]. While this corre-
sponds to a two-fold decrease in P20S-positive vacuoles
(Figure 3(e)), the number of unstained METH-induced
vacuoles increases by 2-fold ([6, 43]; present study in
Figure 1(b)). Remarkably, UP inhibition enhances neuro-
transmitter release [81, 82]; in fact, proteasome inhibitors
produce striatal DA release [83]. This is due to an eﬀect of
proteasome activity in the recycling of short-lived proteins
from and towards the plasma membrane including DA
receptors [84], which is compatible with the retromer
hypothesis for unstained vacuoles expressed above [85]. It
is demonstrated that increased DA stimulation disassembles
the proteasome structure, and it is related to sensitization
[84]. Thus, a vicious circle may establish in which METH-
induced DA release alters the proteasome structure, which
in turn enhances DA release. This issue opens novel avenues
to study the role of protein clearing systems in determining
METH-induced sensitization. Thus, the increase in DA
release occurring after 1 nM METH may be due to altered
proteasome levels shown in this study. This is in line with
imaging of P20S following METH compared with controls
at confocal microscopy. InMETH-treated cells, perimembra-
nous rings of ﬂuorescence appear instead of the diﬀuse ﬂuo-
rescent P20S staining occurring in controls (Figure 4(a)).
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Figure 4: METH reduces the occurrence of the autophagoproteasome (APP) which hosts LC3, P20S, p62, and alpha-synuclein. (a)
Representative immunoﬂuorescence from controls and METH at 72 h. (b) Time-dependent graph of the number of LC3 +P20S-positive
puncta per cell from control and METH at 1μM. (c) P20S, p62, and alpha-synuclein Western blotting on LC3BI-II immunoprecipitates.
(d) Densitometric analysis. Values are given as the optical density detected in four separate replicates (n = 4). Values are given as the mean
number of LC3+ P20S puncta counted in 4 slides. Error bars represent the standard error of the mean. ∗p ≤ 0 05 vs. control. Arrows point
to P20S (red ﬂuorescence) or LC3 (green ﬂuorescence) or merge P20S and LC3 (orange ﬂuorescence). Scale bar = 6.6 μm.
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The discrepancy between LC3 and P20S immunogold par-
ticles extends to the time course (Supplementary Figure 1). In
fact, for longer time intervals following 10μM METH, LC3
particles increase progressively (Supplementary Figure 1a),
along with LC3-positive vacuoles (Supplementary Figure 1b)
with a decreasing ratio between LC3 in vacuoles and LC3
in cytosol, which is time-dependent (Supplementary
Figure 1c). P20S particles and vacuoles decrease slightly
(Supplementary Figure 1d and Figure 1(e), respectively). The
ratio between P20S in vacuoles and P20S in cytosol was
similar for all time intervals (Supplementary Figure 1f).
This suggests that a loss of compartmentalization for P20S
is maximal already for the lowest dose of METH.
3.5. METH and Autophagoproteasome (APP). In order to
document the occurrence of APP in PC12 cells and its mod-
ulation at various doses and time intervals following METH,
we used confocal microscopy to document the merging
between P20S and LC3 particles. As shown in representative
Figure 4(a), the punctum staining for P20S and LC3 was
fairly merging in baseline conditions, while only some
merging could be detected also following the highest dose
of METH. When we counted the amount of merging puncta
detected at confocal microscopy (Figure 4(b)), these were
markedly reduced following 1μMMETH at each time inter-
val (12 h, 24 h, and 72 h). Conﬁrming the hypothesis that a
chemical binding between LC3 and P20S within vacuoles
exists, we carried outWestern blotting on LC3BI-II immuno-
precipitates from whole cell lysates. In these experimental
conditions, P20S was detected along with p62 (Figures 4(c)
and 4(d)). The occurrence of p62 is the key since, as recently
shown by Cohen-Kaplan et al. [86], p62 is pivotal in shuttling
proteasome subunits within LC3-positive autophagosomes.
In line with the key role played by both ATG and proteasome
to metabolize alpha-synuclein [87, 88], we checked whether
these merging organelles contain alpha-synuclein. In fact,
alpha-synuclein is detected here within immunoprecipitates
(Figures 4(c) and 4(d)). Incidentally, these ﬁndings indicate
why, in biochemical studies, the metabolism of alpha-
synuclein was attributed to ATG, UP, or both, depending
on the study [89–91]. The present research paper demon-
strates at the morphological level the occurrence of a single
organelle hosting both UP and ATG components, which
recruits alpha-synuclein (Figure 4(c)). When analyzed at
ultrastuctural morphometry, these merging units between
P20S and LC3 appear as vacuoles owning diﬀerent shapes
and structures corresponding to autophagoproteasomes
(APPs, Figures 4(a), 5(b), and 5(c)). It is remarkable that,
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Figure 5: METH reduces the occurrence of autophagoproteasomes (APPs) dose-dependently. (a) Representative picture of a PC12 cell (low
magniﬁcation) and an APP vacuole (high magniﬁcation). (b, c) Representative pictures of APP vacuoles stained for both LC3 (10 nm) and
P20S (20 nm) immunogold particles. (d) Dose-dependent graph of the number of LC3 + P20S-positive vacuoles per cell from control and
METH at 72 h. Values are given as the mean number of LC3 +P20S-positive vacuoles counted in 100 cells per group. Error bars represent
the standard error of the mean. ∗p ≤ 0 05 vs. control. Arrows point to free LC3 particles (10 nm); arrowheads point to P20S particles
(20 nm); asterisk (∗) indicates a double membrane (b, c). N= nucleus; AV= autophagic vacuoles; M=mitochondrion. Scale bar = 220 nm.
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according to confocal microscopy, under METH administra-
tion, a marked suppression was counted for APP for each
dose of METH ranging between 1nM and 10μM as shown
in the graph of Figure 5(d). Similarly, just like it was described
for the time course detected at confocal microscopy, even at
TEM, APP was similarly depressed by METH at 12, 24, and
72h (Supplementary Figure 2). The number of APP in
controls (representative Figure 6(a)) and following METH
(Figure 6(b)) was plotted for a regression analysis between
the amount of APPs and the number of dead cells in
controls (graph of Figure 6(c)) and following METH (graph
of Figure 6(d)). A negative correlation was detected between
cell death and the number of APPs with a slope, which was
consistent in control conditions and following METH at
10μM. In fact, in both experimental conditions, cell death
was lesser and lesser when APPs were more and more
expressed. In controls, dead cells exceeded 10% in those
samples owning only a few APPs/cell (roughly 0.6), while
cell death was occluded down to 5% when APPs increased
two-fold (graph of Figure 6(c)). As expected, the percentage
of cell death reached almost 50% following the 10μM dose
of METH, when only a few APPs were produced (roughly
0.1 per cell); in contrast, cell death was toned down to 30%
in those samples in which the amount of APPs was six-fold
higher (roughly 0.6 per cell, graph of Figure 6(d)).
3.6. The Eﬀects of mTOR Modulation on P20S, LC3, and
Autophagoproteasome Related with METH Neurotoxicity.
As previously published, mTOR activity ﬁnely tunes APP
[47]. Therefore, in order to test in the present experiments
the eﬀects of speciﬁc doses of compounds, which are known
to act either as mTOR inhibitors or activators, we measured
the amount of the downstream product of mTOR activity
(pS6). Asparagine is a well-known mTORC1 activator [92]
while rapamycin is the gold standard mTORC1 inhibitor
[93, 94]. The doses of these compounds were tested as
reported in Figure 7. Asparagine at the dose of 50mM acti-
vates mTOR while rapamycin at the dose of 100 nM inhibits
mTOR as calculated by the amount of Western blotted pS6.
Therefore, owning the right compounds at appropriated
doses, we tested the eﬀects of these compounds on cell
death and amount of APPs. As shown in representative
micrographs of Figure 8, we observed a variety of eﬀects,
which are in line with the key role of mTOR in METH toxic-
ity and APP stimulation [80, 94, 95]. In fact, the dose of
10μM METH produces roughly 35% cell death, which was
totally prevented by rapamycin (100 nM). Remarkably, rapa-
mycin alone further reduced cell death signiﬁcantly below
levels found in control cells. This witnesses for the presence
of a baseline inherent aberrancy of mTOR regulation in this
cell line, which is reminiscent of neurodegeneration [49].
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Incidentally, this is the ﬁrst report showing that the gold
standard inhibitor of mTOR rapamycin prevents METH tox-
icity. This key ﬁnding provided here as side observation is in
need of a dedicated experimental project. So far, only taurine
andmelatonin were shown to slightly prevent METH toxicity
with an indirect evidence of mTOR-mediated mechanisms
[94, 96], although this was interpreted using a multifaceted
hypothesis. Remarkably, recent evidence, despite not
addressing directly METH neurotoxicity, demonstrated that
METH-induced behavioral sensitization associates with
mTOR overexpression, while rapamycin reverts such an
eﬀect [97]. Again, the stimulation of DA D1 receptors, which
are key in both METH-induced toxicity and behavioral sen-
sitization [9, 98], directly promotes mTOR activation while
inhibiting autophagy [99].
The present study directly relates neuroprotection with
mTOR inhibition, while showing that METH impairs
autophagy. This was consolidated by the deleterious eﬀects
of asparagine. In fact, in the graph of Figure 8(b), we found
that asparagine alone was slightly increasing the natural cell
death occurring in control cells but it did not really increase
much the amount of METH-induced cell death. When all
the three compounds were coadministered, the protective
eﬀects of rapamycin prevailed, with a robust suppression of
cell death occurring following METH+asparagine (graph
of Figure 8). These data concerning cell death were almost
mirrored by each treatment in the count of APPs. In
detail, METH suppressed APPs while rapamycin increased
their number almost two-fold of controls. Asparagine, as
expected, depressed APPs similarly to METH, while the
combination METH+asparagine produced the lowest
number of APPs (3-fold less than controls). It is remark-
able that rapamycin rescued the loss of APPs induced
following either asparagine alone or asparagine +METH
(Figure 8(c)). This strengthens the signiﬁcance of the pres-
ent data concerning the role of mTOR in tuning METH
toxicity and APPs in a reciprocal pattern.
Here, we wish to emphasize the protective eﬀects ofmTOR
inhibition on natural cell death which occurs in the PC12 cell
line. In fact, these cells possess an inherent aberrancy, which is
useful in understanding neuronal degeneration [49]. This is
partly due to an aberrancy in DA compartmentalization and
vesicle polarization, where in baseline conditions most neuro-
transmitter is docking to the cell membrane, making this cell
line highly prone to produce massive amount of self-oxidized
DA metabolites [49]. It is remarkable that upgrading APPs
through mTOR inhibition erases such an inborn trend to
degenerate. Since UP inhibition enhances DA release, which
is related to METH toxicity, it is expected that mTOR
activation, by inhibiting UP activity and compartmentaliza-
tion, enhances METH-induced cell death. The present
research seems to uncover the molecular determinants of
inherent vulnerability of the DA-PC12 cell line, by targeting
speciﬁcally mTORC1 complex dysregulation.
3.7. The Eﬀects of mTOR Modulation on Unstained Vacuoles.
When these experimental conditions were applied to
unstained vacuoles (representative picture of Supplementary
Figure 3), data obtained were quite similar to APPs, though
with some exceptions. In fact, METH increases the number
of unstained vacuoles, which were further increased by
rapamycin alone, way more compared with LC3-positive
vacuoles (roughly 20 per cell and roughly 8 per cell,
respectively). This adds further information about the
previous question concerning the nature of these unstained
vacuoles, which turn out to be mTOR-dependent.
Unexpectedly, combined administration of METH and
rapamycin instead of further increasing the number of
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Figure 7: Modulation of pS6 levels underlie mTOR inhibition and activation by rapamycin and asparagine, respectively. (a) Representative
SDS-PAGE immunoblotting of pS6 protein. (d) Densitometric analysis. Values are given as the optical density detected in six separate
replicates (n = 6). Error bars represent the standard error of the mean. ∗p ≤ 0 05 vs. control; ∗∗p ≤ 0 05 vs. control and METH.
ASN= asparagine; RAP= rapamycin.
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unstained vacuoles compared with rapamycin alone
produces a decrease in these vacuoles (which remain higher
than controls). It is likely that, in the presence of
rapamycin, there is no longer an oxidative stress, which
produces an altered vesicle traﬃcking. In fact, mTOR
inhibition stimulates both the activity and the amount of
the proteasome subunit, which suppresses DA release.
Thus, according to the hypothesis that unstained vacuoles
are due to DA release and proteasome dysfunction
mutually enhancing each other, it is expected that
rapamycin occludes this component. Thus, combined
METH and rapamycin administration produces a number
of unstained vacuoles which is still higher than controls but
lower than rapamycin alone. Asparagine alone or in
combination with METH decreased unstained vacuoles,
which were brought up to control the levels by adding
rapamycin (Supplementary Figure 3).
These data suggest that the mechanisms by which
unstained vacuoles are increased are diﬀerent following
rapamycin compared with METH administration, since
double treatment occludes this eﬀect instead of enhanc-
ing it. This is consistent with the opposite eﬀects on cell
death, which is induced by METH and rescued by rapa-
mycin. In contrast, APP vacuoles despite being decreased
by METH were increased by rapamycin, which witnesses
for a diﬀerent regulation of unstained compared with
APP vacuoles.
3.8. The Eﬀects of mTOR Modulation on LC3. Following
mTOR inhibition by rapamycin, LC3 particles were never
depressed below control values, even when METH and
asparagine were combined. In these experimental conditions,
compartmentalization of LC3 particles within vacuoles was
dramatically enhanced by rapamycin. This mechanism was
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Figure 8: mTOR inhibition prevents cell death and rescues the amount of APPs induced by METH and the mTOR activator asparagine. (a)
Representative micrographs of control and following METH 10 μM, rapamycin 100 nM, and asparagine 50mM, at 72 h. (b) Graph of the
percentage of cell death in control and following METH 10 μM, rapamycin 100 nM, and asparagine 50mM, at 72 h. (c) Graph of the
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the graph in (b), values are given as the percentage of cell counted on 5 grids. For the graph in (c), values are given as the mean number
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independent from the one produced by METH; in fact,
despite METH 10μM was more eﬀective than rapamycin
100 nM to increase total LC3 particles in the cell, rapa-
mycin alone was much more powerful than METH alone
in increasing LC3 within vacuoles (Figure 9(a)). Again,
when rapamycin was combined with METH, a decrease
of vacuolar LC3 was detected compared with rapamycin
alone (Figure 9(b)). This indicates a strong compartmen-
talizing eﬀect of rapamycin, which sharply contrasts with
METH-induced LC3 dispersion (the generalized and non-
speciﬁc increase of LC3 promoted by METH, Figure 9(a)).
The mTOR activator asparagine alone or in combination
with METH further dispersed LC3 particles, since it
decreased the placement of LC3 within vacuoles. This
witnesses for a strong modulation by mTOR of LC3
compartmentalization (Figure 9(c)). This was further evi-
denced by counting the number of LC3 particles in the
vacuoles versus LC3 particles within the cytosol
(Figure 9(d)). In this case, METH decreases the ratio
compared with controls, while rapamycin was increasing
two-fold the ratio compared with controls and reverted
the eﬀects of METH. Asparagine alone was similar to
METH and further suppressed the ratio when it was
combined with METH.
3.9. The Eﬀects of mTOR Modulation on P20S. The eﬀects of
mTOR inhibition were sharply contrasting with the eﬀects
of METH concerning the amount and placement of P20S
particles. In fact, while METH depressed, rapamycin
increased total P20S (Figure 10(a)). Moreover, rapamycin
reverted the suppression induced by METH, while the
eﬀect of asparagine alone was less eﬀective compared with
METH. Combined administration of asparagine and
METH did not alter the eﬀects produced by METH alone.
The eﬀects of asparagine were antagonized by rapamycin.
This was replicated by the number of P20S in the vacuoles
(Figures 10(b) and 10(c)). When counting P20S-positive
vacuoles or P20S in the vacuoles (Figures 10(b) and
10(c), respectively), although the general trend was similar
to what is described in Figure 10(a), there was a remark-
able diﬀerence concerning asparagine. In fact, the polariza-
tion of P20S within vacuoles was dramatically suppressed
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Figure 9: mTOR modulates the number and placement of LC3 particles. (a) The graph shows the number of total LC3 particles per cell in
control, following METH 10 μM, rapamycin 100 nM, and asparagine 50mM, at 72 h. (b) The graph shows the number of LC3-positive
vacuoles per cell in control, following METH 10μM, rapamycin 100 nM, and asparagine 50mM, at 72 h. (c) The graph shows the number
of LC3-positive vacuoles in control and following METH 10μM, rapamycin 100 nM, and asparagine 50mM, at 72 h. (d) The graph shows
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by this mTOR activator even when compared with METH.
Moreover, the eﬀects of asparagine on the dispersion of
P20S was so powerful that even rapamycin was not able
to prevent it (Figure 10(d)).
3.10. Correlation between Autophagoproteasomes and Cell
Death. The eﬀects of all these treatments on the amount
of APPs versus the occurrence of cell death were plotted
in the graph of Figure 11, which remarks for various
mTOR modulators and a powerful negative correlation
between the number of APPs and the number of dead
cells.
In conclusions, the negative correlation which was
described for APP and cell death in controls and following
a 10μM dose of METH (Figure 6) was strengthened by the
analysis carried out with mTOR modulators (Figure 8). This
ﬁnal plotting shows, at one glance, how mTOR inhibition is
key for producing the merging between proteasome and
autophagy to build autophagoproteasome, while it is com-
patible with a strong neuroprotective role exerted by such a
merging organelle.
4. Concluding Remarks
METH administration is known to increase the number of
ATG vacuoles within catecholamine-containing cells. This
was originally published by Cubells et al. [22], and at ﬁrst,
it was suggested to produce ATG-mediated cell damage [22].
Nonetheless, in 2008, we demonstrated that the inhibi-
tion of ATG in METH-treated catecholamine cells instead
of producing neuroprotection worsened METH neurotoxic-
ity indicating a compensatory neuroprotection for ATG
induction during METH toxicity, as conﬁrmed by several
studies [16, 37, 80, 100–102].
In line with this, in the present manuscript, we
demonstrate that rapamycin administration fully rescues
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Figure 10: mTOR modulates the number and placement of P20S particles. (a) The graph shows the number of total P20S particles per cell in
control, following METH 10μM, rapamycin 100 nM, and asparagine 50mM, at 72 h. (b) The graph shows the number of P20S-positive
vacuoles per cell in control, following METH 10μM, rapamycin 100 nM, and asparagine 50mM, at 72 h. (c) The graph shows the number
of P20S-positive vacuoles in control and following METH 10 μM, rapamycin 100 nM, and asparagine 50mM, at 72 h. (d) The graph
shows the ratio between the number of P20S particles within vacuoles and cytosolic P20S particles. Values are given as the mean number
of P20S particles and vacuoles counted in 50 cells per group. Error bars represent the standard error of the mean. ∗p ≤ 0 05 vs. control; ∗∗
p ≤ 0 05 vs. control and METH; #p ≤ 0 05 vs. METH. ASN= asparagine; RAP= rapamycin.
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METH-induced cell death. In the present paper, apart
from strengthening the concept that mTOR inhibition
and ATG protect against METH toxicity, we further detail
the signiﬁcance of speciﬁc ATG-related structures.
It is believed that METH-induced increase in LC3
immunoﬂuorescence is produced by an increase in LC3-
positive stagnant ATG vacuoles with an impairment of
the autophagy ﬂux [37]. However, in the present study,
we demonstrate that, under METH administration, there
is a loss of compartmentalization of LC3 particles within
vacuoles. In fact, LC3 particles increase more in the cyto-
sol than within vacuoles, which represents a novel insight
in ATG and METH toxicity.
This leads to reconsider the signiﬁcance of densely ﬂuo-
rescent LC3 spots detected at confocal microscopy following
METH, since the greatest contribution is provided by free
cytosolic LC3.
In these experimental conditions, the eﬀects of rapamy-
cin are demonstrated to be neuroprotective against cell death
while reinstating vacuolar compartmentalization of both LC3
and P20S.
It is likely that a concomitant acceleration of activity
within stagnant ATG vacuoles may concur to provide neu-
roprotection. In fact, asparagine, which also impairs the
merge between autophagosomes and lysosomes, produces
a dramatic eﬀect.
In these experimental conditions, the occurrence of ATG
vacuoles is further dissected for the concomitant presence of
the P20S proteasome component. It is now well established
that these LC3+P20S vacuoles contain both ATG and pro-
teasome markers and are named “autophagoproteasomes”
(APPs) [48].
In the present study, we demonstrate that LC3+P20S-
positive vacuoles (APP) represents a clearing compartment
which behaves distinctly and sometimes opposite to classic
ATG (LC3-positive) compartment. This speciﬁc compart-
ment correlates with cell survival. In line with this, alpha-
synuclein, which is known to buﬀer oxidative species [103,
104], is involved in METH toxicity, since in alpha-
synuclein knockout mice, a potentiation of METH-induced
nigrostriatal damage occurs [105]. The coimmunoprecipita-
tion of alpha-synuclein within APPs found here corroborates
such a neuroprotective eﬀect. This novel organelle may coun-
teract also impaired mitophagy during METH administra-
tion. In fact, few key steps in mitochondrial removal are
carried out by proteasome components acting during early
autophagosome formation [39, 106, 107].
As a proof of principle, we cannot be satisﬁed yet,
since one might argue that a defect in ATG progression
may lead ATG vacuoles not to be able to take up the pro-
teasome component due to a failure in the p62-driven
uptake of ubiquitinated proteasomes. When such an alter-
native explanation is consistent, then an increased amount
of P20S should be measured in the cytosol. However, the
number of P20S in the cytosol was decreased by METH
administration, and it was further suppressed by the con-
comitant administration of asparagine.
Again, if the decreased amount of UP within ATG vacu-
oles were related to a decrease of ATG progression (impaired
shuttling of P20S within ATG vacuoles), the ratio between
cytosolic vs. vacuolar P20S should be modiﬁed by METH,
while this ratio stays steady.
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Supplementary Materials
Supplementary Figures 1, 2, and 3: further evidence about
various METH-induced ultrastructural alterations. In all
these graphs, the dose of METH was kept constant 10μM.
Supplementary Figure 1: the time dependency of METH-
induced variations in LC3 and P20S particles (12 h, 24 h,
and 72h). Counts refer to whole cytosol or selectively within
vacuoles. Moreover, the ratio between compartmentalized
particles within vacuoles and total cytosolic particles at these
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Figure 11: Inverse correlation between cell death and amount of
APPs following mTOR modulation. The dashed line shows the
amount of APPs while the continuous line shows the percentage
of cell death. For each treatment, the values of the two lines
produce a mirror image, which indicates a negative correlation.
∗p ≤ 0 05 vs. control; ∗∗p ≤ 0 05 vs. control and METH; #p ≤
0 05 vs. METH. ASN= asparagine; RAP= rapamycin.
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time intervals is reported. Supplementary Figure 2: the time
dependency of METH-induced suppression of APPs, which
concerns selectively with the number of LC3+P20S-positive
vacuoles (autophagoproteasomes) in the whole cytosol. Sup-
plementary Figure 3: the number of unstained vacuoles in the
whole cytosol following various single and combined treat-
ments with mTOR modulators. (Supplementary Materials)
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